Abida Sultana

Dr. Abida Sultana


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
PKPawan Kumar
Pawan Kumar
ARArindam Ray
Arindam Ray
ASAmrita Singh
Amrita Singh
ASAbida Sultana
Abida Sultana
RHRhythm Hora
Rhythm Hora
ADArup DebRoy
Arup DebRoy
Background: Globally, pneumonia claims the lives of about 700,000 children under the age of 5 every year. Pneumococcal conjugate vaccine (PCV) was introduced in India phase-wise, beginning in high-burden states, and the rollout was completed nationwide by 2021—representing a major initiative by the Ministry of Health and Family Welfare (MoHFW). Despite the challenges posed by the COVID-19 pandemic, the campaign succeeded in maintaining progress and achieving nationwide coverage. This narrative review highlights the significant decisions, processes, and coordinated efforts of the various stakeholders involved that led to this successful PCV rollout. Methodology: A comprehensive desk review of both published and unpublished literature relevant to pneumonia burden and the efficacy and effectiveness of PCVs, along with documentation of PCV introduction and the scale-up was carried out. Results: The documentation of the PCV journey has been broken down into four sections: pre-introduction, PCV Phase-I introduction, pan-India rapid expansion, and the period post-introduction. Since the nationwide rollout in 2021, PCV coverage in India has steadily increased, reflecting successful immunization efforts. WUENIC, which is an annual WHO, and UNICEF estimates of national immunization coverage also show a positive trend in vaccination coverage (PCV booster coverage = 25% (2021), rising to 83% (2023), aligning with the goals of the WHO and UNICEF’s Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD). Conclusions: The phased rollout was an ambitious effort by the MoHFW, which was particularly challenging given the overlap with the COVID-19 pandemic. Despite these hurdles, the MoHFW, along with strong collaboration from development partners and stakeholders, successfully navigated the complex rollout. Future studies on the role of PCVs in reducing antibiotic resistance and the economic benefits of PCV introduction could help policymakers sustain funding and prioritize vaccine procurement decisions.

27 May 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
RMRashmi Mehra
Rashmi Mehra
ARArindam Ray
Arindam Ray
ASAmrita Singh
Amrita Singh
AKAmanjot Kaur
Amanjot Kaur
RHRhythm Hora
Rhythm Hora
ADArup DebRoy
Arup DebRoy
Background: Human papillomavirus (HPV) is a leading cause of cervical cancer. It has a substantial impact on global public health, with low- and middle-income countries, including India, facing the highest burden. In 2022, India reported 127,526 new cases and 79,906 deaths due to cervical cancer, projected to increase by 61% by 2040. Although the National Technical Advisory Group on Immunization recommended the HPV vaccine for cervical cancer prevention, it is yet to be a part of India’s universal immunization program. Objective: This study aims to examine online interest in the HPV vaccine in India from January 2010 to April 2024 using Google Trends. Methods: A cross-sectional analysis of Google Trends data was performed, using the relative search volume to track interest on a scale of 0‐100. Trends were analyzed annually using 1-way ANOVA and joinpoint regression to identify significant changes in search behavior related to public health events. Statistical significance was set at P<.05. Results: The average annual growth in HPV vaccine-related searches was 13.7% (95% CI 7.9%‐19.1%), with the highest relative search volume in 2024 (49.5) and the lowest in 2017 (3.38). Spikes in search interest aligned with key events like the 2018 National Technical Advisory Group on Immunization recommendation and the 2022 launch of the indigenous HPV vaccine. The results highlight online search data’s value in tracking public interest, which fluctuates in response to health policy changes or developments on social media. In India, targeted digital strategies will be vital for addressing vaccine hesitancy and increasing HPV vaccine uptake. Conclusions: Google Trends data can inform public health strategies by identifying periods of high interest, aiding in the promotion of HPV vaccination in India.

20 March 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
PKPawan Kumar
Pawan Kumar
RMRashmi Mehra
Rashmi Mehra
ARArindam Ray
Arindam Ray
ASAmrita Singh
Amrita Singh
KSKapil Singh
Kapil Singh
ADArup DebRoy
Arup DebRoy
Introduction: In 2023, India’s National Technical Advisory Group on Immunization (NTAGI) recommended the inclusion of typhoid conjugate vaccine (TCV) in the Universal Immunization Programme (UIP). However, introducing TCV, an additional injectable vaccine (AIV), will potentially increase the number of injections administered in a single visit to a maximum of five (if given at the 9 to 12 months touchpoint) or four (if given in the second year of life). In this context, the present study aimed to explore the perspectives of program managers, service providers, and caregivers regarding introduction of an AIV in a single visit under the UIP. Methods: A mixed-method study was undertaken wherein quantitative data was collected by telephonic surveys, and qualitative data by key informant interviews (KIIs) and focus group discussions (FGDs). Purposive sampling encompassed eight states, eight districts, eight planning units, and 32 session sites. The qualitative data were thematically analyzed manually using Excel, while the quantitative data was analyzed using STATA 17. Results: A total of 1140 telephonic surveys, 96 KIIs, and 16 FGDs were conducted. The study revealed that program managers mentioned maternal emotional reactions as a significant concern and backed AIV introduction at the 9–12 months touchpoint. Vaccinators and community mobilizers favored the 16–24 months window with combined presentations and mentioned single-dose vials as the preferred approach for vaccine delivery. Caregivers acknowledged the benefits of vaccination but expressed discomfort and fear regarding multiple injections to the child in a single visit. Caregivers expressed a preference for a combination vaccine. No preference was reported among caregivers for the introduction of AIV to the 9–12 or 16–24 months touchpoints. Conclusion: Stakeholders’ perspectives on introducing an additional injectable vaccine in a single visit under the UIP are diverse. These will be helpful in developing an effective strategy for the future introduction of AIV under UIP.

1 September 2025 in INQUIRY: The Journal of Health Care Organization, Provision, and Financing
Verified
Journal Article
Open access
PKPawan Kumar
Pawan Kumar
ARArindam Ray
Arindam Ray
RHRhythm Hora
Rhythm Hora
AKAmrita Kumari
Amrita Kumari
KSKapil Singh
Kapil Singh
ARArup Deb Roy
Arup Deb Roy
Cervical cancer remains the fourth most common cancer among women globally, despite being preventable with the human papillomavirus (HPV) vaccine. However, HPV vaccine uptake remains a challenge in low- and middle-income countries (LMICs), where cervical cancer elimination faces significant delays. The present study aims to identify the social determinants impacting HPV vaccine uptake in LMICs. This systematic review and meta-analysis included studies published between 2010 and 2025, identified through PubMed, Google Scholar, and ScienceDirect. Eligible studies reported HPV vaccine uptake (initiation, completion, or both) among adolescent girls aged 9 to 19 and examined at least 1 individual- or household-level social determinant. Data were thematically synthesized, and a meta-analysis was conducted using the random-effects model, with results expressed as odds ratios (ORs), with 95% confidence intervals (CIs). Eight studies, conducted in Ethiopia, Tanzania, and Uganda, were included. Key determinants assessed included age, religion, residence, parental education, occupation, wealth index, marital status, and household factors. Meta-analyses revealed wealth index (OR = 1.34; 95% CI: 1.05-1.70; P = .02) and parental marital status (OR = 0.86; 95% CI: 0.78-0.95; P < .01) as significant predictors of HPV vaccine uptake among adolescent girls in LMICs. Other factors, such as age, residence, parental education, etc., showed inconsistent effects or no significant association, with high heterogeneity across studies limiting the generalizability of some findings. This review highlights the complex, context-specific individual and household factors influencing HPV vaccine uptake among adolescent girls in LMICs. While wealth index and parental marital status showed consistent associations, other factors varied across studies. Community-based, culturally sensitive, tailored interventions are critical to improve the vaccine uptake. Continued research with standardized mixed-methods is vital to address multilevel factors and ensure equitable HPV vaccine uptake in LMICs.

20 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
PKPawan Kumar
Pawan Kumar
ARArindam Ray
Arindam Ray
ASAmrita Singh
Amrita Singh
ASAbida Sultana
Abida Sultana
RHRhythm Hora
Rhythm Hora
ADArup DebRoy
Arup DebRoy
Background: Pneumonia is one of the leading causes of death in under-5 children in India. The phased rollout, which began in high-burden states and was completed nationwide by 2021, was a major initiative by the Ministry of Health and Family Welfare (MoHFW). Despite challenges posed by the COVID-19 pandemic, which affected logistics and required creative solutions, the campaign succeeded in maintaining progress and achieving nationwide coverage. This narrative review highlights the significant decisions, dedication and coordinated efforts of various stakeholders involved that led to accomplishment of successful PCV rollout. Methodology: A comprehensive desk review of both published and unpublished literature relevant to the burden of pneumonia, pneumococcal pneumonia mortality in children under five, the efficacy and effectiveness of Pneumococcal Conjugate Vaccines (PCVs), and the documentation of PCV introduction and scale-up in India was carried out. Results: The documentation of PCV journey has been broken down in four sections: pre-introduction, PCV Phase I introduction, Pan India rapid expansion, and post-introduction. Since the nationwide rollout in 2021, PCV coverage in India has steadily increased reflecting successful immunization efforts. The WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) also show a positive trend in vaccination coverage, which aligns with the goals of the WHO and UNICEF’s Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD). Conclusion: The phased rollout, starting with high-burden states and completing nationwide expansion by 2021, was an ambitious effort by the Ministry of Health and Family Welfare (MoHFW), particularly challenging given the overlap with the COVID-19 pandemic. Despite these hurdles, the MoHFW, with strong collaboration from development partners and stakeholders, successfully navigated the complex rollout. This is a noteworthy achievement considering the unprecedented scale of the COVID-19 vaccination drive that was simultaneously ongoing.

26 August 2025 in medRxiv
Verified
Preprint
Open access
PDF file
PKPawan Kumar
Pawan Kumar
ARArindam Ray
Arindam Ray
RHRhythm Hora
Rhythm Hora
AKAmrita Kumari
Amrita Kumari
KSKapil Singh
Kapil Singh
ADArup DebRoy
Arup DebRoy
Objective With the rising misuse of benzodiazepine (BZD) and associated overdose deaths, cannabis has been touted as a potential substitute with proposed benefit of better health outcomes. This two-year retrospective analysis examined whether cannabis use among BZD users was associated with changes in outcomes of (1) all-cause mortality, (2) hospitalizations, (3) emergency department (ED) visits, and (4) whether it demonstrated BZD-sparing effects on prescription quantity over time. Methods Using data from Yale New Haven Health System, we conducted a retrospective, longitudinal cohort study among BZD users. Cannabis use was the primary exposure, with BZD users without cannabis exposure as controls. Using inverse probability of treatment weighting and propensity score matching techniques, cohorts were balanced at baseline adjusting for medical comorbidities, socioeconomic status and other clinical factors. Kaplan-Meier curves and Cox proportional hazard models were examined with four outcomes of interest. Results The sample included 1,026 patients with 60.3% females and mean age was 54.2. There was no significant effect of cannabis use on BZD quantity. Cannabis use was not significantly associated with all-cause mortality, hospitalization, or ED visits. In exploratory analysis, medical cannabis users had a lower risk of all-cause mortality but greater risk for hospitalizations among those aged < 50 years. Conclusion In this longitudinal cohort study, cannabis use was not significantly associated with all-cause mortality, hospitalization and ED visits, or benzodiazepine dose reduction. Our results do not support a benzodiazepine-sparing effect for cannabis use.